Validation of Nomograms for Survival and Metastases after Hysterectomy and Adjuvant Therapy in Uterine Cervical Cancer with Risk Factors

Table 2

Log-rank tests for overall survival, distant metastases-free survival, and disease-free survival.

	5-year OS; (%)	Log-Rank test; value	5-year DMFS; (%)	Log-Rank test; value	5-year DFS; (%)	Log-Rank test; value
Age (years)		0.029 (between all)		0.403 (between all)		0.200 (between all)
≤40	70.7	0.006 (≤40 : 41–64)	81.8	0.259 (≤40 : 41–64)	74.7	0.074 (≤40 : 41–64)
41–64	92.2	0.326 (≤40 : ≥65)	89.6	0.953 (≤40 : ≥65)	86.0	0.523 (≤40 : ≥65)
≥65	93.8	0.500 (41–64 : ≥65)	76.2	0.294 (41–64 : ≥65)	80.2	0.782 (41–64 : ≥65)
FIGO stage		0.481 (between all)		0.712 (between all)		0.335 (between all)
Ia	100.0	0.385 (Ia : Ib)	100.0	0.450 (Ia : Ib)	100.0	0.240 (Ia : Ib)
Ib	89.0	0.331 (Ia : IIa)	86.1	0.424 (Ia : IIa)	83.9	0.169 (Ia : IIa)
IIa	83.6	0.433 (Ib : IIa)	83.7	0.773 (Ib : IIa)	75.7	0.441 (Ib : IIa)
Histology		0.494		0.987
Squamous	88.8		86.3
Others	85.0		84.8
Serum SCC antigen (ng/mL)		0.278		0.218		0.176
≤1.5	88.8		89.8		87.8
>1.5	84.4		85.0		79.0
Tumor size (cm)		<0.001		<0.001		0.058
≤4	94.7		92.5		86.7
>4	64.3		59.6		66.7
Depth of cervix invasion		0.162		0.300		0.255
≤1/2	100.0		90.3		87.6
>1/2	84.1		85.1		81.5
Parametrial invasion		0.093		0.383		0.300
Negative	90.7		87.1		84.6
Positive	72.2		79.4		73.3
Resection margin involvement		0.432		0.413		0.612
Negative	88.3		87.3		83.4
Positive	86.7		79.4		80.8
Lymphovascular invasion		0.417		0.080		0.124
Negative	92.4		90.8		86.6
Positive	83.6		81.1		78.7
Lymph node involvement		0.061 (between all)		0.010 (between all)		0.033 (between all)
0	92.8	0.265 (0 : 1-2)	89.6	0.551 (0 : 1-2)	87.8	0.604 (0 : 1-2)
1-2	82.6	0.009 (0 : ≥3)	87.0	0.001 (0 : ≥3)	83.3	0.006 (0 : ≥3)
≥3	60.0	0.407 (1-2 : ≥3)	55.6	0.098 (1-2 : ≥3)	50.0	0.174 (1-2 : ≥3)
Concurrent chemotherapy		0.895		0.554		0.871
No	92.8		82.0		82.5
Yes	86.3		88.4		84.0

OS: overall survival; DMFS: distant metastases-free survival; DFS: disease-free survival.